LCTX
Lineage Cell Therapeutics, Inc.
$1.21
+1.68%
$301.7M
No data for this timeframe.
Vol
Market Cap$301.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders8 funds
Inst. Value$24.8M
Inst. Activity2 buys / 3 sells
Insider Activity1B / 0S
Insider Net $$24.4K
SEC Reports3
Exchange NYSE·Sector Biological Products, (No Diagnostic Substances)·Inc. CA·CIK 0000876343·Prev Close $1.19
Recent Activity
May 12, 2026
SEC
Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss of $4.8M ($0.02 bas
8-K — Impact 3/10
May 12, 2026
earnings_calendar
LCTX Q1 2026 Earnings Scheduled — 2026-05-12
Mar 24, 2026
SEC
Lineage Cell Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to sell unspecified
EFFECT — Impact 4/10
Mar 12, 2026
Insider
Culley Brian M bought 15,000 shares
President and CEO @ $1.63 ($24.4K)
Mar 5, 2026
SEC
Lineage Cell Therapeutics reported its 2025 financial results, showing a significant increase in revenue to $14.6 millio
8-K — Impact 6/10
Mar 5, 2026
Insider
Culley Brian M sold 3,250,000 shares
President and CEO @ $0.00 ($0.00)
Mar 5, 2026
Insider
Howe Jill Ann sold 1,050,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
2,404,800 shares ($4.0M)
Price Targets
$5.50
+350.8% upside
Strong Buy
Current $1.22
Low $3.00
Median $4.50
High $9.00
6 analysts
$3.00
$9.00
Analyst Ratings
3Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 25, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 6, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.02 | $-0.04 — $0.02 | 87% YoY | 4 |
| Next Q | $-0.03 ▼ -50.0% | $-0.04 — $-0.02 | 77% YoY | 4 |
| Current FY | $-0.07 ▼ -10.0% | $-0.14 — $0.04 | 70% YoY | 5 |
| Next FY | $-0.09 ▼ -16.1% | $-0.15 — $0.04 | -36% YoY | 5 |
Latest Reports
NEUTRAL
8-K
3/10
Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss of $4.8M ($0.02 bas
May 12, 2026
NEUTRAL
EFFECT
4/10
Lineage Cell Therapeutics' shelf registration (Form S-3) has become effective, allowing the company to sell unspecified
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $16.1M | — |
| RENAISSANCE TECHNOLOGIES LLC | $4.0M | ADD |
| MORGAN STANLEY | $3.3M | ADD |
| TWO SIGMA INVESTMENTS, LP | $443.5K | TRIM |
| BANK OF AMERICA CORP | $330.4K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 12, 2026 | Culley Brian | BUY | $24.4K |
| Mar 5, 2026 | Culley Brian | A | $0.00 |
| Mar 5, 2026 | Howe Jill | A | $0.00 |
| Mar 5, 2026 | Samuel George | A | $0.00 |
| Feb 11, 2026 | Samuel George | M | $0.00 |
8 institutional holders with $24.8M total value (14,850,979 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,644,276 | $16.1M | 64.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 2,404,800 | $4.0M | 16.2% | ADD +26.2% |
| 3 | MORGAN STANLEY | 1,998,663 | $3.3M | 13.5% | ADD +98.6% |
| 4 | TWO SIGMA INVESTMENTS, LP | 265,585 | $443.5K | 1.8% | TRIM -25.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 197,849 | $330.4K | 1.3% | DOUBLED +126.0% |
| 6 | FMR LLC | 191,960 | $320.6K | 1.3% | — |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 129,909 | $216.9K | 0.9% | TRIM -40.5% |
| 8 | WELLS FARGO & COMPANY/MN | 17,937 | $30.0K | 0.1% | TRIM -36.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,905,633 | 2,404,800 | +26.2% | $4.0M | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,006,451 | 1,998,663 | +98.6% | $3.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 354,347 | 265,585 | -25.0% | $443.5K | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 218,274 | 129,909 | -40.5% | $216.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 28,151 | 17,937 | -36.3% | $30.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 103,312 | 233,436 | +126.0% | $394.5K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 68,275 | 218,274 | +219.7% | $368.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 480,423 | 317,977 | -33.8% | $288.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 160,973 | 103,312 | -35.8% | $93.7K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 503,193 | 68,275 | -86.4% | $62.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 113,446 | 27,827 | -75.5% | $25.3K | 2025-Q2 |
| MORGAN STANLEY | ADD | 660,061 | 968,781 | +46.8% | $437.5K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 301,544 | 480,423 | +59.3% | $217.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 136,775 | 59,372 | -56.6% | $26.8K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 197,100 | 2,283,072 | +1058.3% | $1.1M | 2024-Q4 |
| UBS Group AG | ADD | 171,431 | 220,888 | +28.8% | $110.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 64,800 | 136,775 | +111.1% | $68.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 71,367 | 94,894 | +33.0% | $47.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 526,629 | 848,291 | +61.1% | $768.0K | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 416,223 | — | $376.8K | 2024-Q3 |
3 unique insiders with 1 transactions. Net insider value: $24.4K ($24.4K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Culley Brian M | President and CEO | BUY | 15,000 | $1.63 | $24.4K |
| Mar 5, 2026 | Culley Brian M | President and CEO | A | 3,250,000 | $0.00 | $0.00 |
| Mar 5, 2026 | Howe Jill Ann | Chief Financial Officer | A | 1,050,000 | $0.00 | $0.00 |
| Mar 5, 2026 | Samuel George A. III | General Counsel and Secretary | A | 900,000 | $0.00 | $0.00 |
| Feb 11, 2026 | Samuel George A. III | General Counsel and Secretary | M | 6,075 | $0.00 | $0.00 |
| Feb 11, 2026 | Samuel George A. III | General Counsel and Secretary | F | 2,502 | $1.80 | $4.5K |
| Feb 11, 2026 | Samuel George A. III | General Counsel and Secretary | M | 6,075 | $0.00 | $0.00 |
| Feb 11, 2026 | Culley Brian M | President and CEO | M | 31,250 | $0.00 | $0.00 |
| Feb 11, 2026 | Culley Brian M | President and CEO | F | 12,869 | $1.80 | $23.2K |
| Feb 11, 2026 | Culley Brian M | President and CEO | M | 31,250 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
3/10
Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss
May 12, 2026
NEUTRAL
EFFECT
4/10
Lineage Cell Therapeutics' shelf registration (Form S-3) has become effective, allowing the company
Mar 24, 2026
MIXED
8-K
6/10
Lineage Cell Therapeutics reported its 2025 financial results, showing a significant increase in rev
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.50 mean target
+350.8% upside
Strong Buy (3.00)
$3.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.22 |
| Target Low | $3.00 |
| Target Mean | $5.50 |
| Target Median | $4.50 |
| Target High | $9.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.02 | $-0.04 | $0.02 | 86.5% | — | — | $0.0B | 87.1% | 4 |
| Next Q 2026-09-30 |
$-0.03 | $-0.04 | $-0.02 | 76.9% | -50.0% | 0↑ 1↓ | $0.0B | -21.3% | 4 |
| Current FY 2026-12-31 |
$-0.07 | $-0.14 | $0.04 | 69.5% | -10.0% | 1↑ 1↓ | $0.0B | 23.2% | 5 |
| Next FY 2027-12-31 |
$-0.09 | $-0.15 | $0.04 | -36.4% | -16.1% | — | $0.0B | 0.9% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.018 | |
| 7d ago | $-0.018 | +0.000 |
| 30d ago | $0.000 | -0.018 |
| 60d ago | $0.000 | -0.018 |
| 90d ago | $-0.010 | -0.008 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 25, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 6, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
LCTX Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
LCTX Q1 2026 Earnings Scheduled — 2026-05-07
Mar 5, 2026
earnings_calendar
LCTX Q4 2025 Earnings After Market Close — 2026-03-05